In the News
The Burrill Report interviews Greg Scott on WuXi/CRL breakup and China's hot IPOs
 
Greg Scott joined Foley's Eye on China webinar on life science innovation
>>Foley webinar...
Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

Sinovac Closes $9.8 Million Follow-on Offering

publication date: Jan 23, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Sinovac Biotech Ltd., a Beijing based developer of vaccines, placed 2.5 million shares with a single accredited investor, raising $9.75 million in gross proceeds. The price was $3.90 per share, a slight increase over the closing price of Sinovac yesterday of $3.76. At its current price, Sinovac has a trailing 12 months P/E ratio of 25 and a market capitalization of $149 million. Revenues for the first nine months of 2007 are increasing at a 160% rate over 2006, and the company made a nine-month profit of $5.7 million on $24.3 million of revenue, a margin of 23%. More details... 

Stock Symbol (AMEX: SVA)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
ChinaBio® Events
BioBay Investor Forum 2010
Suzhou, China
November 3 - 4, 2010
China Forum 2010
Munich, Germany
November 14, 2010

 
ChinaBio® Investor Forum 2010 - Guangzhou
Guangzhou, China
December 21, 2010
Partner Events
BioPharm America™ 2010
Boston, MA, USA
September 15–17, 2010

CALAsia 2010
San Diego, USA
October 4-5, 2010

CHINA PRETRIALS 2010: Global Preclinical Development Summit
Beijing, China
October 17-19, 2010

CHINA TRIALS 2010
Beijing, China
November 7-9, 2010

12th Shanghai International Forum on Biotechnology & Pharmaceutical Industry (BIO-FORUM)
Beijing, China
November 9-11, 2010
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners